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Functional Plasticity of Central TRPV1 Receptors
in Brainstem Dorsal Vagal Complex Circuits of
Streptozotocin-Treated Hyperglycemic Mice
Andrea Zsombok,1,2Muthu D. Bhaskaran,1Hong Gao,2 Andrei V. Derbenev,1,2 and Bret N. Smith1
1Department of Physiology, University of Kentucky College of Medicine, Lexington, Kentucky 40536, and 2Department of Physiology, Tulane University,
Health Sciences Center, New Orleans, Louisiana 70112
Emerging data indicate that central neurons participate in diabetic processes by modulating autonomic output from neurons in the
dorsal motor nucleus of the vagus (DMV). We tested the hypothesis that synaptic modulation by transient receptor potential vanilloid
type 1 (TRPV1) receptors is reduced in the DMV in slices from amurinemodel of type 1 diabetes. The TRPV1 agonist capsaicin robustly
enhanced glutamate release onto DMV neurons by acting at preterminal receptors in slices from intact mice, but failed to do so in slices
fromdiabeticmice. TRPV1 receptor protein expression in the vagal complexwasunaltered. Brief insulin preapplication restoredTRPV1-
dependent modulation of glutamate release in a PKC- and PI3K-dependent manner. The restorative effect of insulin was prevented by
brefeldin A, suggesting that insulin induced TRPV1 receptor trafficking to the terminal membrane. Central vagal circuits critical to the
autonomic regulation of metabolism undergo insulin-dependent synaptic plasticity involving TRPV1 receptor modulation in diabetic
mice after several days of chronic hyperglycemia.
Introduction
Type-1 diabetes (T1D) is an autoimmune disease resulting from
destruction of insulin-secreting pancreatic islet cells (Tisch and
McDevitt, 1996). Diabetes has been handled mainly as a periph-
eral metabolic disease, but accumulating evidence indicates that
the brain plays a critical role in regulating glucose homeostasis via
activity of neurons controlling autonomic functions (Oomura,
1980; Undeland et al., 1998; Schwartz and Porte, 2005).
Along with key hypothalamic nuclei, the brainstem dorsal va-
gal complex (DVC) plays an important role in the autonomic
control of feeding, regulation of pancreas and liver metabolism,
and other autonomic functions. Neurons in the DVC are able to
respond to both hypoglycemia and hyperglycemia (Ferreira et al.,
2001; Balfour et al., 2006; Balfour and Trapp, 2007), consistent
with their critical role in whole-body energy homeostasis. Acute
hyperglycemia or increased glucose concentration in the DVC
tends to inhibit vagal output, whereas chronic hyperglycemia
causes vagal nerve activity to increase (Laury et al., 1991; Ahre´n et
al., 1996). Chronically altered vagal function is common in dia-
betic patients (see Zsombok and Smith, 2009). Hepatic glucose
production is altered in diabetes, and this substantially involves
central autonomic circuits controlling vagal output to the liver
(Pocai et al., 2005a,b; Lam et al., 2010). Intact hepatic vagal out-
put is required for a significant portion of the inhibition of glu-
coneogenesis following central or peripheral administration of
insulin, suggesting that increased circulating insulin levels affect
neural circuits required to restrainhepatic gluconeogenesis (Pocai et
al., 2005b).
The role of transient receptor potential vanilloid type 1
(TRPV1) in diabetes was recently demonstrated (Suri and Szal-
lasi, 2008) and suggests that events controlling T1D development
and glucose dysregulation are not only immunological, but also
neurological (Tsui et al., 2007). Several reports,mainly associated
with diabetic neuropathy, indicate that peripheral TRPV1 recep-
tor activity and protein levels are altered in diabetic models.
In primary afferent neurons, TRPV1 expression is upregulated
(Rashid et al., 2003), and significant increases in capsaicin sensi-
tivity and proton-activated inward currents were observed in an-
imals with streptozotocin (STZ)-induced diabetes (Hong and
Wiley, 2005). In sensory neuron homogenates, total TRPV1 pro-
tein was decreased, but increased protein levels were detected on
plasma membranes (Hong and Wiley, 2005). Insulin enhanced
TRPV1-mediated currents in heterologous expression systems
and cultured primary sensory neurons (Van Buren et al., 2005).
These observations suggest that deficiencies in insulin signaling
and/or enhanced glucose-dependent mechanisms contribute to
altered TRPV1 function and complications of diabetes.
Centrally, activity of TRPV1 potently modulates synaptic in-
put to motor neurons of the dorsal motor nucleus of the vagus
(DMV), which ultimately regulates visceral function (Derbenev
et al., 2006). TRPV1 activity in the DMV alters, for example,
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gastrointestinal function, but central attributes of TRPV1 function
associatedwithdiabeteshavenotbeen identified.Here,we tested the
hypothesis that TRPV1 is functionally downregulated in an insulin-
dependent fashion inputativepreganglionicparasympatheticmotor
neurons of the DMV in amousemodel of T1D, andwe determined
the cellular mechanism underlying the effect of insulin on TRPV1-
mediated synaptic modulation in these neurons.
Materials andMethods
Animals. Male CD-1 mice (5–8 weeks old; Harlan) were used for these
experiments. Animals were housed in a vivarium under 12 h light, 12 h
dark cycle with food and water available ad libitum. The University of
Kentucky and Tulane University Animal Care and Use Committees ap-
proved all animal procedures.
Streptozotocin injection.Mice were fasted overnight (6–10 h) and then
injected intraperitoneally with STZ (200 mg/kg; Alexis Biochemicals)
dissolved in 0.1 M citrate buffer, at pH 4.5. Control animals received
citrate buffer injections. Body weight and blood glucose levels (One
Touch Ultra) were monitored before injection and then daily afterward.
Micewith blood glucose levels300mg/dl (16.6mM) for at least 3 dwere
considered to be hyperglycemic and were used for further experiments.
Brainstem slice preparation. Acute brainstem slices containing the
DMV were prepared from male control and STZ-treated hyperglycemic
CD-1mice. Animals were deeply anesthetized by halothane inhalation to
effect (Sigma) and then decapitated. The brain was removed and im-
mersed in an ice-cold (0–4°C) artificial CSF (aCSF) bubbled with 95%
O2–5%CO2. The composition of aCSF was (inmM): 124 NaCl, 3 KCl, 26
NaHCO3, 1.4 NaH2PO4, 11 glucose, 1.3 CaCl2, and 1.3 MgCl2, pH 7.3–
7.4. Transverse brainstem slices (i.e., coronal plane; 300 m) containing
the DMV were cut with a vibratome. The slices were transferred to a
holding chamber, which contained oxygenated aCSF at 34–36°C for 1 h
before being transferred to a recording chamber mounted on the fixed
stage of an upright microscope (Olympus BX51WI; or Nikon FN1).
Whole-cell patch-clamp recordings.Whole-cell patch-clamp recordings
were performed at 34–36°C under visual control on an upright, fixed
stage microscope equipped with infrared illumination and differential
interference contrast optics (IR-DIC). For whole-cell patch-clamp re-
cordings, electrodes (2–5M) were filled with a solution containing the
following (in mM): 130 Cs-gluconate, 1 NaCl, 5 EGTA, 10 HEPES, 1
MgCl2, 1 CaCl2, 3 CsOH, 2–3 Mg-ATP, pH 7.3–7.4, adjusted with 5 M
CsOH. EPSCs were examined at a holding potential of60 or70 mV.
Electrophysiological signals were recorded using an Axoclamp 700B am-
plifier (Molecular Devices), low-pass filtered at 2 kHz, and stored to a
computer using aDigidata 1440Adigitizer and pClamp10 software (Mo-
lecular Devices). Synaptic currents were analyzed offline using pClamp
10 and MiniAnalysis 6.0.3. (Synaptosoft).
Drug application. All recordings were performed with tetrodotoxin
(TTX; 1M) in the aCSF solution to block action potentials andmonitor
mEPSCs. The TRPV1 receptor agonist capsaicin (1 M; Tocris Biosci-
ence), the TRPV1 antagonist capsazepine (CPZ, 10 M) or the TRPV1
antagonist 5-iodoresiniferatoxin (5-iRFT, 1M; Tocris Bioscience), the
TRPV4 agonist 4-phorbol 12,13-didecanoate (4--PDD, 1 M; Alexis
Biochemicals), and the Golgi disrupting agent brefeldin A (5M, Sigma)
were dissolved in ethanol and diluted in aCSF (final concentration of
ethanol 0.01% by volume). A PKC activator, phorbol 12-myristate
13-acetate (PMA, 1–3 M, Tocris Bioscience); a PKC inhibitor, GF
109203X (BIM, 500 nM or 2M; Tocris Bioscience); and a PI3K inhibitor,
wortmannin (3 M; Sigma), were dissolved in DMSO and diluted in
aCSF (final DMSO concentration 0.01%). Insulin (1 M, Novolin R,
Novo Nordisk) was diluted in aCSF.
Statistical analysis. The effect of agonists and antagonists on mEPSC
frequency and amplitude were analyzed within individual cells using the
Kolmogorov–Smirnov test by comparing 2 min epochs before and after
drug application (200 events each condition). The effects of agonists
and antagonists across the neuron groups were analyzed using a paired
two-tailed Student’s t test, and effects between different groups were
analyzed using one-way ANOVA. Number of replicates (i.e., n) is neu-
rons recorded, with numbers of mice also indicated for each experiment;
probability values over the 95% confidence level (p 0.05) were consid-
ered significant; averages obtained across neurons are expressed as the
mean SEM.
Western blot detection and quantification. Transverse (i.e., coronal)
sections of the brainstem (400 M) were made from control and STZ-
treated hyperglycemic mice using a vibratome, and the caudal DVC was
microdissected to include the DMV and nucleus tractus solitarius. The
samples were homogenized at 4°C in lysis buffer (0.5 MHEPES, 3 MNaCl,
1 M MgCl2, 0.5 M EDTA, 0.1 M DTT, 10% SDS, 10% deoxycholate, and
0.3%TritonX-100) and centrifuged at 13,000 rpm at 4°C for 10min. The
supernatant was collected, leaving the pellet behind. Proteins were quan-
tified using Bradford protein assay. Each lane was loaded with 15 g of
protein in 7.5%TrisHCl polyacrylamide gels and electrophoresed at 110
V for 60–90 min. Proteins were then transferred at 200 mA for 1 h to
polyvinylidene difluoride membranes for Western blot analysis. Mem-
branes were rinsed in PBS and blocked in 1:1 Odyssey blocking buffer/
PBS (Odyssey, Li-COR Biosciences) for 1 h at room temperature.
Membranes were then either incubated 1 h at room temperature or over-
night at 4°C, with an anti-rat VR1N terminus (1:2500) (Neuromics) and
an anti-mouse -actin (1:1000) primary polyclonal antibodies (Sigma)
in 1:1 Odyssey blocking buffer/PBS/0.1% Tween 20. Following four 5
min washes (PBS  0.1% Tween 20), membranes were incubated with
fluorescence-conjugated goat anti-rabbit IRDye-680 and goat anti-
rabbit IRDye-800 secondary antibodies (IgG; 1:5000 Odyssey) in Odys-
sey blocking buffer/PBS/0.1%Tween 20 and 0.01% SDS for 1 h, followed
by four 5minwashes. After a final 10minPBSwash, themembraneswere
dried and blots were scanned by a densitometer (Odyssey model 9120,
Li-COR Biosciences) to quantify band density. Background density was
subtracted from the VR1 band density and normalized to -actin, which
was used as the loading control. Western blots were analyzed using
single-factor ANOVA. Results are reported as the mean SEM; signifi-
cance was set at p 0.05 for all statistical measures.
Results
TRPV1 activity is altered in STZ-treated hyperglycemic mice
Injection of STZ (200 mg/kg; i.p.) resulted in hyperglycemia
within 3 d (300 mg/dl; 16.6 mM), which was maintained for up
to 1 week. The mean blood glucose level in STZ-treated mice
measured 4 d after the injection (528.1 13.4mg/dl, n 53) was
significantly higher than in control mice (178.7 3.4 mg/dl, n
40; p 0.05). Animals were used for experiments 3–7 d after STZ
treatment.
Synaptic input tomotor neurons of the DMVpotently regulates
autonomic output to the viscera. The frequency and amplitude of
action potential-independent miniature EPSCs (mEPSCs) in the
DMV was examined in the presence of TTX (1 M) in slices from
control andSTZ-treatedhyperglycemic animals,maintained innor-
mal artificial CSF (aCSF). To analyze the effect of 3–7 d of continu-
ous hyperglycemia and insulin deficiency on TRPV1 receptor
activity in theDMV, the TRPV1 agonist capsaicinwas appliedwhile
recording synaptic currents in DMV neurons, voltage clamped at
60 or 70 mV. Similar to effects in rats (Derbenev et al., 2006),
bath application of capsaicin (1 M) significantly and consistently
increased the frequency of mEPSCs in DMV neurons from control
mice (Fig. 1A), and this occurred regardless of the anatomical posi-
tion of the neuron within the nucleus. The effect of capsaicin was
observed within 2 min of the drug reaching the slice and was maxi-
mal by 5 min. Under control conditions, the average mEPSC fre-
quency was 11.0 1.9 Hz (range 3.4–20.6 Hz; n 10 cells from 5
mice). After application of capsaicin (1M), the mean frequency of
mEPSCs increased to 17.1 3.8 Hz (range 8.1–42.9 Hz, 69 16%
increase; n  10; p  0.05; Fig. 1A,C,E). There was no significant
change inmEPSCamplitude after capsaicin application, confirming
that the agonist acted at presynaptic glutamatergic terminals to en-
hance glutamate release (Derbenev et al., 2006). The average ampli-
tude in neurons from control mice was 16.2 1.8 pA (range 8–27
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pA) and 16.9 2.3 pA (range 8–30 pA; p
0.05) after applicationof capsaicin. InDMV
cells in slices fromcontrolmice,mEPSC fre-
quency, butnot amplitude,was significantly
enhanced by capsaicin, similar to results in
rats (Derbenev et al., 2006).
Unlike responses in slices from intact
mice, application of capsaicin did not in-
crease the frequency of mEPSCs in DMV
neurons from STZ-treated, hyperglyce-
micmice (Fig. 1B,D,E). Under control re-
cording conditions (i.e., normal aCSF
with TTX), the mean mEPSC frequency
was 14.4  3.5 Hz (range 2.0–35.7 Hz;
n 12 from 6 mice). After application of
capsaicin, the average frequency of mEP-
SCs was unchanged (16.2 4.0 Hz; 15
11% change; range 2.3–43.8 Hz; p 
0.05). The amplitude of mEPSCs in neu-
rons from STZ-treated hyperglycemic
mice was 15.8 1.1 pA (range 11–23 pA)
and 17.9 1.7 pA after application of cap-
saicin (range 12–33 pA; p  0.05). The
selective effect of capsaicin onmEPSC fre-
quency in control mice was significantly
greater than in STZ-treated mice (p 
0.05; Fig. 1).
The background mEPSC frequency
was significantly higher in slices from
STZ-treated, hyperglycemic mice than in controls (p 0.01; Fig.
2A–C). The average mEPSC frequency was 8.9  0.9 Hz (range
1.4–24.2Hz; n 35 from 16mice) in control animals and 13.7
1.3 Hz (range 2.7–35.7 Hz; n 44 from 18 mice) in STZ-treated
hyperglycemic animals (Fig. 2A). To determine whether the in-
creased frequency—and therefore the lack of agonist effect—in
STZ-treated mice was due to tonic endogenous TRPV1 activity,
the effect on mEPSC frequency of a TRPV1 receptor antagonist,
5-iRFT, was examined. Application of 5-iRFT (1 M) did not
result in a significant change in the frequency ofmEPSCs in STZ-
treated hyperglycemic or control animals (Fig. 2D). In neurons
from STZ-treated, hyperglycemic mice, the average frequency
was 14.8 2.1 (range 10.3–22.9Hz) before application of 5-iRFT
and 12.4  4.6 Hz (range 7.5–26.3 Hz; n  5; p  0.05) after
antagonist application. Another TRPV1 antagonist, capsazepine,
was also without effect in any of three cells. Application of 5-
iRFT (1M) alone did not altermEPSC frequency in controlmice
(n 5; p 0.05; Fig. 2D), but prevented the increase in mEPSC
frequency upon capsaicin application.
TRPV1 receptor protein expression
was not altered in STZ-treated hyperglycemic mice
Since the ability of TRPV1 receptor activation to enhance gluta-
mate release in the DMV was diminished in slices from STZ-
treated hyperglycemic mice, the relationship between altered
TRPV1 receptor activity and changes in receptor protein expres-
sion in the DVC was investigated. The DVC was microdissected
from slices of control and STZ-treated hyperglycemic mice.
Western blot analyses were made to compare TRPV1 levels in
control and STZ-treated hyperglycemic mice. A discrete band at
95 kDa, corresponding to the molecular weight of the TRPV1
receptor, was identified byWestern blot, consistentwith previous
studies using this antibody (Stein et al., 2006; Bhaskaran and
Smith, 2010). Western blot analysis identified no significant dif-
ference in TRPV1 protein expression between the two groups
(n  8; p  0.05; Fig. 3), suggesting that the altered response to
TRPV1 activation was not due to diminished TRPV1 expression
in STZ-treated hyperglycemic mice.
Incubation with insulin restores the TRPV1 activity
Slices from STZ-treated, hyperglycemic mice were preincubated
with insulin (1 M; 30  10 min) to determine the effect of
insulin restoration onTRPV1 function (Fig. 4).When comparing
cells from insulin-treated slices with cells from control slices,
there was a small but nonsignificant effect of insulin alone on
mEPSC frequency in slices fromSTZ-treated hyperglycemicmice
(13.7 1.3 Hz; n 44 versus 8.8 2.1 Hz; n 10 with insulin;
p  0.05; unpaired t test). However, preincubation with insulin
restored the effect of capsaicin onmEPSC frequency. The average
mEPSC frequency in slices fromSTZ-treated hyperglycemicmice
in the continuous presence of insulin for several minutes was
8.8  2.1 Hz (range 0.6–22.2 Hz; n  10 from 6 mice). In the
continued presence of insulin, bath application of capsaicin (1
M) significantly increased mEPSC frequency in each cell tested
to 14.6 3.7 Hz (82 12% increase; n 10; range 1.1–33.2 Hz;
p 0.05). The magnitude of the capsaicin-induced increase was
significantly greater than in neurons from STZ-treated hypergly-
cemic animals without insulin incubation (p  0.05; Fig. 4B),
and was similar to the capsaicin-induced increase seen in control
mice (i.e., 69  16%; p  0.05). These data indicate that acute
exposure to insulin can restore TRPV1 receptor functionality in
DVC neurons from STZ-treated mice.
Insulin modulates TRPV1 receptor activity in a PI3K/
PKC-dependent manner
Blocking PKC
TRPV1 receptors are known to be sensitive to PKC modulation
(Van Buren et al., 2005). Insulin binds insulin receptors (IRs) in
Figure 1. TRPV1 activation increases mEPSC frequency in control, but not in STZ-treated hyperglycemic mice. A, Sample of
continuous recording of mEPSC frequency observed in DMV neuron from a control mouse in the presence of tetrodotoxin (TTX; 1
M). Upper trace, control (i.e., TTX only). Bath application of capsaicin (1M) increasedmEPSC frequency (lower trace).B, Similar
recording of mEPSCs in a DMV neuron from a STZ-treated hyperglycemic mouse (upper trace). Bath application of capsaicin had
little effect on mEPSCs. C, D, Cumulative event probability plots of interevent interval distribution in 2 min recordings from DMV
cells in slices fromcontrol (C) andSTZ-treated (D)mice.E, Combineddata showing theeffect of capsaicin in control andSTZ-treated
mice. Capsaicin increased mEPSC frequency in neurons from control animals but failed to increase mEPSC frequency in
neurons from STZ-treated hyperglycemic animals. Asterisk indicates significance (p 0.05). The number of replicates is
shown above each bar.
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the brain and, via insulin receptor substrate 2, a functional com-
ponent of the IR, activates PI3K and elevates the level of PKC in
cultured primary sensory neurons (Van Buren et al., 2005). To
determine whether insulin acted via a PKC-dependent mechanism
to restore theTRPV1 receptor activity in theDMV inhyperglycemic
mice, the effect of a selective and potent PKC inhibitor, bisindolyl-
maleimide I (BIM) on the capsaicin-induced increase in mEPSC
frequencywas tested in slices fromSTZ-treatedhyperglycemicmice.
Slices were preincubated with insulin (1 M) and BIM (500 nM-2
M) for 30min andmEPSCs were recorded before and after capsa-
icin (1M) application. The average frequency before capsaicin ap-
plicationwas 10.0 2.1Hz (range 2.1–25.0Hz,n 9 from4mice).
Application of capsaicin failed to increasemEPSCs frequency in the
presence of insulin plus the PKC inhibitor (10.8  2.3 Hz; range
2.3–25.9; 8 4% change; p 0.05). Inhibition of PKC activity with
BIM prevented the insulin-induced restoration of the capsaicin ef-
fect in slices from STZ-treated animals (Fig. 5).
We also tested the effect of BIM on slices from control ani-
mals, and observed that in the presence of 500 nM BIM, capsaicin
failed to cause a significant increase in the mEPSC frequency,
suggesting that the effect of capsaicin also required PKC activity
under normal conditions. In this set of control mice, the average
mEPSC frequency was 11.6  2.6 Hz (range 1.9–21.5 Hz) and
was 12.7  2.4 Hz (range 2.3–21.2 Hz) after application of cap-
saicin (1 M) in the presence of BIM (n  7 from 3 mice; p 
0.05).
PKC activation
To verify the involvement of PKC in the reinstatement of TRPV1
function by insulin, we preincubated the slices from STZ-treated
animals with a PKC activator, phorbol 12-myristate 13-acetate
(PMA; 3 M; 20 min). Similar to the effect of insulin, preincuba-
tion of the slices with PMA restored the
effect of capsaicin (Fig. 5). In slices from
STZ-treated hyperglycemic mice in the
presence of PMA, the average mEPSC fre-
quencywas 14.3 4.4Hz (range 2.9–48.3
Hz) before capsaicin application and was
increased to 24.7  9 Hz by the addition
of the TRPV1 agonist in each cell tested
(84  17% increase; range 4.9–57.1 Hz;
n 10 from 6 mice; p 0.05; Fig. 5).
The PI3K pathway
Toverify that the restorationof the response
to capsaicin observed after incubation with
insulin was due to increased PI3K activity,
we examined the effect of thePI3K inhibitor
wortmannin on neurons from STZ-treated
hyperglycemicmice. Preincubation of slices
with wortmannin (3 M) plus insulin (1
M) diminished the ability of insulin to re-
store sensitivity to capsaicin (1 M) versus
the restored effect in the presence of insulin
alone. In the presence of wortmannin plus
insulin, the average mEPSC frequency be-
fore was 14.5 3.0Hz (range 1.4–34.4Hz)
andwas 19.1 3.9Hz after addition of cap-
saicin (range 1.1–40.1 Hz; n  10 from 4
mice;p0.05; Fig. 5). In slices fromcontrol
mice,wortmannin incubationbefore capsa-
icin application did not influence the effect
of capsaicin. Capsaicin increased mEPSC
frequency by 81  30% in the presence of
wortmannin alone in controls, similar to the increase in the absence
of wortmannin (p 0.05). TRPV1 receptor-mediated modulation
of glutamate release does not require PI3K activity in intact or STZ-
treated hyperglycemic animals, but PI3K is required for the full
insulin-dependent restoration of capsaicin’s effect in slices from
STZ-treated, hyperglycemic mice.
Insulin-dependent TRPV1 receptor translocation
Insulin has been shown to induce rapid delivery of functional
TRPV1 receptors to the plasma membrane in cultured DRG cells
and in heterologous expression systems (Van Buren et al., 2005).
Since totalTRPV1proteinexpression(i.e., assessedbyWesternanal-
ysis) was similar between the two groups, we reasoned that the
insulin-dependent reinstatement of TRPV1 receptor function in the
DMV involved receptor translocation to synaptic terminal mem-
brane.To test this hypothesis, brefeldinAwaspreapplied to slices for
10–55 min to disrupt the Golgi apparatus and interfere with recep-
tor trafficking, followed by the addition of insulin for 30 min. The
averagemEPSC frequency in thepresence of brefeldinA (5M)plus
insulin (1 M) was 15.5  3.1 Hz (range 2.2–32.9 Hz) and was
18.2 2.9Hz (range 2.2–33.3Hz) after addition of capsaicin (1M;
n  11 from 5 mice; p  0.05). Preincubation of the slices from
STZ-treated, hyperglycemic animals with brefeldin A prevented the
insulin-dependent reinstatement of theTRPV1-mediated enhanced
glutamate release (Fig. 5).
TRPV4 sensitivity was not altered after STZ treatment
To assess the possibility that TRP receptors were nonspecifically
altered in slices from STZ-treated mice, the function of a close
TRP family member, TRPV4, was assessed. The effect of the se-
lective TRPV4 agonist 4-PDD was examined in control and
Figure 2. Miniature EPSC frequency was significantly higher in DMV neurons from STZ-treated hyperglycemic mice compared
to controls. A, Mean group differences in mEPSC frequency in normal and STZ-treated mice. Number of neurons in each group is
indicated in parentheses. Asterisk indicates significance between thegroups (p0.05).B, Sample recordings ofmEPSCs observed
at holding potential of60 mV in neurons from control (upper trace) and STZ-treated hyperglycemic (lower trace) mice. C,
Combined data showing the distribution of mEPSC frequencies for cells from control and STZ-treated hyperglycemic mice. D,
Application of the TRPV1 antagonist 5=-iRFT did not significantly changemEPSC frequency in neurons from control or STZ-treated
animals, indicating that latent TRPV1 activity was not responsible for the increasedmEPSC frequency in treatedmice. The number
of replicates is shown above each bar.
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STZ-treated hyperglycemic animals. Application of 4-PDD (1
M) resulted in a significant increase in mEPSC frequency in
slices from both control and STZ-treated hyperglycemic mice
(p  0.05). The effect of 4-PDD was observed within 2 min of
the drug reaching the slice and was maximal by 5 min. The fre-
quency of mEPSCs was increased 50 12% by 4-PDD in DMV
neurons from control animals (10.7 1.8Hz; range 1.4–15.2Hz,
control; 16.3 3 Hz, range 2–24.8 Hz, 4-PDD; n 7; p 0.05;
Fig. 6B). Similarly, application of 4-PDD increasedmEPSC fre-
quency by 68 14% in DMV neurons from STZ-treated hyper-
glycemic animals (from 12.1  3.1 Hz; range 1.1–25.6 Hz,
control; 19.3 5.1 Hz; range 2.2–41.9 Hz, 4-PDD; n 8; p
0.05). There was no significant difference in themagnitude of the
effect between the two groups, suggesting that TRPV4 function
remained intact in STZ-treated hyperglycemic animals.
Discussion
Elevated glucose can acutely alter cellular function in the vagal
complex (Ferreira et al., 2001; Balfour et al., 2006), and chroni-
cally altered excitability in neurons is often associated with com-
pensatory, plastic changes in receptor function. Here, the
TRPV1-mediated enhancement of glutamate release in the DMV
was suppressed after 3–7 d of frank hyperglycemia due to STZ-
induced insulin depletion, even when glucose concentration in
the sliceswas normalized and identical between groups of record-
Figure 3. TRPV1 expression levels were not different in STZ-treated hyperglycemic mice. A,
Western blot showing a band at 95 Kd, consistent with TRPV1 expression in the vagal complex
from control and STZ-treated hyperglycemic mice. Actin was used as a loading control. B,
Western blot densitometry analysis detected no significant difference in TRPV1 protein levels
between control and STZ-treated mice. The number of replicates is shown above each bar.
Figure 4. The TRPV1 receptor-mediated increase in glutamate release was reinstated in
STZ-treated hyperglycemic mice in the presence of exogenously applied insulin. A, Sample
recordingsofmEPSCsobservedatholdingpotential at60mV in thepresenceof insulin (1M;
upper trace). Preincubation of the slices with insulin for 20 min restored the capsaicin-induced
increase inmEPSC frequency (bottom trace).B, Cumulative event probability plots of interevent
interval distribution in recordings from STZ-treated mice in the presence of insulin (control)
and insulin capsaicin. C, Mean group changes in mEPSC frequency showing the effect of
capsaicin inSTZ-treatedhyperglycemicmice in theabsenceandpresenceof insulin. Thenumber
of replicates is shown inparentheses aboveeachbar; theasterisk indicates significantdifference
in the effect of capsaicin in the presence of insulin (p 0.05).
Figure 5. Insulin modulates TRPV1 receptor activity in a PI3 kinase- and PKC-dependent
manner. Mean group changes inmEPSC frequency showing the effect of capsaicin under differ-
ent conditions. Significant differences between effects of capsaicin onmEPSC frequency in DMV
neurons from control mice versus those from STZ-treated hyperglycemic mice are illustrated
(see Fig. 1). The restorative effect of insulin is also shown (see Fig. 4). Activation of PKC by the
addition of PMA restored the effect of capsaicin in slices from STZ-treated hyperglycemic mice.
Inhibition of PKC or PI3 kinase activity with BIM or wortmannin, respectively, diminished the
ability of insulin to restore the capsaicin-induced mEPSC frequency increase in STZ-treated,
hyperglycemic mice. Brefeldin A, which disrupts Golgi function and receptor trafficking, also
prevented the restorative effect of insulin on TRPV1-modulated glutamate release. Asterisks
indicate significant mEPSC frequency differences between neurons tested in the presence of
insulin alone versus in insulin plus kinase or Golgi inhibitors (p 0.05). The number of repli-
cates is shown above each bar.
Figure 6. TRPV4 receptor activity was not altered in STZ-treated hyperglycemic mice. A,
Sample trace showing mEPSCs in DMV neuron from an STZ-treated hyperglycemic mouse in
control aCSF (upper trace) and in the presence of 4PDD (1M; lower trace), a selective TRPV4
receptor agonist. B, Mean group changes in mEPSC frequency showing similar magnitude of
4PDD-induced increase in control and STZ-treated hyperglycemic mice. Bath application of
4PDD significantly increasedmEPSC frequency in both control and STZ-treatedhyperglycemic
mice (p 0.05). The number of replicates is shown above each bar.
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ings. Prolonged hyperglycemia can induce vagally stimulated in-
sulin release (Laury et al., 1991) and can result in tonically altered
vagus nerve activity (Ahre´n et al., 1996), independent of insulin
availability. Hyperglycemia is associated with increased
GABAergic tone in the DVC (Ferreira et al., 2001). Chronic hy-
perglycemia may alter synaptic balance sufficiently to contribute
to the functional receptor changes observed here, including a
possibly compensatory increase in glutamatergic contribution.
Diminished TRPV1-mediated glutamate release is consistent
with reduced synaptic excitation and therefore decreased vagal
motor tone, which would be expected to contribute to diabetic gas-
troparesis accompanying vagal dysregulation (Saltzman andMcCa-
llum, 1983). Moreover, since vagal activity tends to inhibit hepatic
gluconeogenesis, altered excitability of DMV neurons would be ex-
pected to contribute to hepatic glucose dysregulation.
In addition to chronic hyperglycemia, the absence of insulin
signaling may also have contributed to an internalization of
TRPV1 receptors in synaptic terminals. Consistent with this hy-
pothesis, preapplication of insulin or a PKC activator reinstated
the effects of capsaicin. Acute blockade of PKC in slices from
normal animals prevented capsaicin’s effect, whereas disruption
of PKC activity or of receptor trafficking prevented the insulin-
dependent reinstatement of TRPV1 to enhance glutamate release
in STZ-treated hyperglycemic animals. Although a number of
factorsmight be responsible for the diminished TRPV1 function,
chronically elevated glucose levels and/or diminished insulin lev-
els seem likely to be themost salient features of the effect. Restor-
ing TRPV1 function by insulin or PKC modulation may
represent an avenue for restoring DMV neuron activity and nor-
malizing parasympathetic output in diabetic patients.
The role of the CNS in diabetes
Type-1 diabetes is generally conceptualized as an autoimmune,
metabolic disorder due to-cell loss.However, a growing body of
evidence suggests that the brain plays an important role in the
regulation of energy balance and glucose metabolism (Sandoval
et al., 2008; Zsombok and Smith, 2009). It is generally accepted
that there is a specific central network receiving afferent informa-
tion regarding the status of peripheral metabolism via hormonal
signaling, which is relevant to energy/glucose balance and regu-
lation (Pocai et al., 2005b; Perez-Tilve et al., 2006; Sandoval et al.,
2008). This central network, which includes the DVC, connects
the brain with peripheral metabolic processes in the viscera, in-
cluding hepatic gluconeogenesis, gastrointestinal motility, diges-
tion, and pancreatic exocrine function (Barber and Burks, 1987;
Ferreira et al., 2001; Pocai et al., 2005b). These observations sup-
port the hypothesis that disruption of the normal physiological
balance between sympathetic and parasympathetic output due to
dysregulated central synaptic function is a key factor promoting
development of the metabolic syndrome.
The autonomic network is centered in hypothalamus and
brainstem circuits, which are robustly interconnected. Roles for
hypothalamic and brainstem neurons in energy regulation have
been demonstrated (Sandoval et al., 2008). Administration of
insulin to the paraventricular nucleus (PVN) induced suppres-
sion in hepatic gluconeogenesis, which was mediated by the va-
gus (Pocai et al., 2005b). Specific alteration of glutamate activity
in the DVC also affects hepatic glucose production (Lam et al.,
2010). The DVC plays a critical role in the autonomic parasym-
pathetic control of energy homeostasis via the vagus nerve, and
modulation of neural circuits in this area profoundly alters diges-
tive and metabolic processes.
The TRPV1 receptor in the brain
The importance of TRPV1 receptor in peripheral sensory systems
during diabetes has been established (Razavi et al., 2006; Suri and
Szallasi, 2008), but the role of central TRPV1 receptors is not yet
as clear. The existence of TRPV1, a nonselective cation channel,
has been demonstrated in the brain (Mezey et al., 2000; Cristino
et al., 2006), including in DVC where it can be activated by cap-
saicin or anandamide (Derbenev et al., 2006), resulting in en-
hanced glutamate release. Notably, anandamide also binds
cannabinoid receptors in the DVC (Derbenev et al., 2004), acti-
vation of which, if unopposed by TRPV1 binding, would tend to
inhibit glutamate release. The expression of TRPV1 is altered
peripherally in several diseases affecting metabolism, including
diabetes. Activation of PKC induces TRPV1 activity in the ab-
sence of another agonist and potentiates the response of TRPV1
to capsaicin (Premkumar and Ahern, 2000). Stimulating PKC
with PMA reinstated the TRPV1-mediated enhancement of
mEPSC frequency in STZ-treated hyperglycemic mice. This is
consistent with the observation that application of BIM, a PKC
inhibitor, prevented the capsaicin-induced enhancement of
mEPSC frequency in control slices, which further supports the
involvement of PKC in TRPV1 activation and enhancement of
glutamate release centrally.
The present results in central motor circuits demonstrate that
TRPV1 receptor activity is diminished in the brainstem of STZ-
treated, hyperglycemic mice in an insulin-dependent fashion.
However, a reduction in total TRPV1 protein expression levels
was not detected in the DVC of T1D mice and the TRPV1-
mediated response was reinstated by PKC upregulation, suggest-
ing that the receptors were present but functionally unavailable.
In the periphery, insulin traffics glucose transporters to themem-
brane to allow cellular glucose utilization (Kahn and Cushman,
1985). In addition to sensitizing TRPV1 receptors, PKC can also
traffic the receptor to the plasma membrane in cultured cells
(Van Buren et al., 2005). Application of brefeldin A disrupts re-
ceptor trafficking in the vagal complex (Browning et al., 2004)
and disrupting receptor trafficking with brefeldin A prevented
the insulin-induced reinstatement of the capsaicin effect. Simi-
larly, insulin potentiates TRPV1 function inXenopus oocytes and
neuroblastoma cells (Lilja et al., 2007) in a PI3K- and PKC-
dependent manner, effects that were due to increased protein
expression, increased receptor sensitivity, and membrane trans-
location (Morenilla-Palao et al., 2004). Our findings are consis-
tent with the hypothesis that insulin potentiates TRPV1 receptor
function on glutamatergic synaptic terminals in the DMV by
translocating them to the synaptic terminalmembrane in a PI3K-
and PKC-dependent manner. Unlike TRPV1, the functional
expression of TRPV4, which has also been demonstrated to be
located centrally (Liedtke et al., 2000; Gu¨ler et al., 2002), was not
altered, indicating that a nonspecific alteration in TRP family
expression or function did not occur.
Insulin in the brain
Insulin crosses the blood–brain barrier via a saturable transport
mechanism (Margolis and Altszuler, 1967; Banks, 2004) and is
transported into the brainstem and hypothalamus over twice as
rapidly as into whole brain (Banks, 2004), which highlights the
importance of these brain areas in glucosemetabolism. The brain
is insulin independent with respect to glucose utilization, but
neuronal insulin receptors are expressed in the DVC (Pardini et
al., 2006), and centrally acting insulin regulates peripheral energy
homeostasis and glucosemetabolism (Obici et al., 2002; Schwartz
and Porte, 2005). Here, we show that application of insulin onto
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slices from STZ-treated hyperglycemic animals rapidly restores
the capsaicin-induced increase inmEPSC frequency, suggesting a
partial reconstitution by insulin of normal synaptic control of
vagal output in these animals. The effect of insulin on reinstate-
ment of TRPV1-dependent effects in preganglionic vagal neu-
rons that regulate visceral function represents a potentially novel,
insulin-dependent means of regulating metabolism centrally.
The connection between TRPV1 and insulin
The mEPSC frequency was significantly higher in the brainstem
of STZ-treated hyperglycemic mice than in controls, suggesting
tonically increased glutamate release in these animals. We tested
the hypothesis that the increased mEPSC frequency was due to
tonic TRPV1 activation, which could obscure the effects of
TRPV1 agonists. However, significant TRPV1 antagonist-
induced changes inmEPSC frequencywere not detected, indicat-
ing that the enhancedmEPSC frequencywas unlikely to be due to
increased tonic TRPV1 activity. In the hippocampus, insulin en-
hances NMDA receptor function, increasing channel opening
probability by enhancing the number of NMDA receptors in the
cell membrane andNR1 subunit surface expression (Skeberdis et
al., 2001), but insulin-induced alteration of glutamate receptor
function was not overt in the DMV. The basis for the tonically
elevated glutamate release in the DMV of STZ-treated hypergly-
cemic mice remains a subject for future investigation.
Modulation of central TRPV1 function suggests altered DMV
output in STZ-treated, hyperglycemic mice, which may contrib-
ute to altered glucose metabolism by decreasing the ability of
TRPV1binding to alter excitability ofDMVneurons that regulate
liver, pancreas, or gastrointestinal viscera. This would be consis-
tent with a dysregulation of hepatic gluconeogenesis, and gastro-
intestinal responses might include diminished digestive reflexes,
depending on the type of postganglionic circuit targeted by the
DMVneuron.Whether insulin sensitivity of this circuit is altered
in type 2 diabetes is not known, but development of insulin re-
sistance in the DVC could similarly contribute to the develop-
ment of diabetic symptoms. The observations here support an
emerging and significant role of central TRPV1 in regulating and
responding to glucose and insulin levels in patients with diabetes,
as well as indicating a novel cellular mechanism of insulin-
dependent regulation of synaptic modulation in neurons.
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